Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $5.2 million.

  • Lyell Immunopharma's Share-based Compensation fell 3135.66% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.3 million, marking a year-over-year decrease of 2738.64%. This contributed to the annual value of $33.1 million for FY2024, which is 2960.67% down from last year.
  • Per Lyell Immunopharma's latest filing, its Share-based Compensation stood at $5.2 million for Q3 2025, which was down 3135.66% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Share-based Compensation ranged from a high of $22.4 million in Q2 2022 and a low of $5.0 million during Q2 2025
  • Moreover, its 5-year median value for Share-based Compensation was $12.7 million (2021), whereas its average is $12.7 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 10981.01% in 2021, then crashed by 5391.28% in 2023.
  • Lyell Immunopharma's Share-based Compensation (Quarter) stood at $21.2 million in 2021, then fell by 13.29% to $18.4 million in 2022, then crashed by 53.91% to $8.5 million in 2023, then dropped by 4.49% to $8.1 million in 2024, then crashed by 35.27% to $5.2 million in 2025.
  • Its Share-based Compensation was $5.2 million in Q3 2025, compared to $5.0 million in Q2 2025 and $6.0 million in Q1 2025.